These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25992488)

  • 1. Effects of a selective aldosterone blocker and thiazide-type diuretic on blood pressure and organ damage in hypertensive patients.
    Ohta Y; Ishizuka A; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
    Clin Exp Hypertens; 2015; 37(7):569-73. PubMed ID: 25992488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension.
    Ohta Y; Kamide K; Hanada H; Morimoto S; Nakahashi T; Takiuchi S; Ishimitsu T; Tsuchihashi T; Soma M; Tomohiro Katsuya T; Sugimoto K; Rakugi H; Oukura T; Higaki J; Matsuura H; Shinagawa T; Miwa Y; Sasaguri T; Igase M; Miki T; Takeda K; Higashiura K; Shimamoto K; Katabuchi R; Ueno M; Hosomi N; Kato J; Komai N; Kojima S; Sase K; Iwashima Y; Yoshihara F; Horio T; Nakamura S; Nakahama H; Miyata T; Kawano Y
    Hypertens Res; 2020 Mar; 43(3):220-226. PubMed ID: 31748705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.
    Elnagar N; Satoh M; Hosaka M; Asayama K; Ishikura K; Obara T; Mano N; Ohkubo T; Imai Y
    Clin Exp Hypertens; 2014; 36(2):83-91. PubMed ID: 24625334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension.
    Kalizki T; Schmidt BMW; Raff U; Reinold A; Schwarz TK; Schneider MP; Schmieder RE; Schneider A
    J Clin Hypertens (Greenwich); 2017 Jul; 19(7):669-676. PubMed ID: 28211216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study.
    Kobalava ZD; Kotovskaya YV; Villevalde SV; Moiseev VS;
    Curr Med Res Opin; 2009 Sep; 25(9):2229-37. PubMed ID: 19622008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home.
    Hashimoto J; Hirayama H; Hanasawa T; Watabe D; Asayama K; Metoki H; Kikuya M; Ohkubo T; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 May; 27(4):331-41. PubMed ID: 15921070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters.
    Inaba M; Noguchi Y; Yamamoto T; Imai T; Hatano M; Yagi S; Katayama S
    Hypertens Res; 2004 Mar; 27(3):141-5. PubMed ID: 15080372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
    Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
    Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Add-on Therapy Consisting of a Selective Mineralocorticoid Receptor Blocker on Arterial Stiffness in Patients with Uncontrolled Hypertension.
    Shibata T; Tsutsumi J; Hasegawa J; Sato N; Murashima E; Mori C; Hongo K; Yoshimura M
    Intern Med; 2015; 54(13):1583-9. PubMed ID: 26134187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.
    Okamura K; Shirai K; Totake N; Okuda T; Urata H
    Clin Exp Hypertens; 2018; 40(2):99-106. PubMed ID: 28692311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors.
    Brand S; Amann K; Mandel P; Zimnol A; Schupp N
    PLoS One; 2014; 9(12):e115715. PubMed ID: 25551569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of additional administration of low-dose indapamide on patients with hypertension treated with angiotensin II receptor blocker.
    Yamada H; Mishiro Y; Kusunose K; Sata M
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):145-50. PubMed ID: 20200326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS; Muskala P; Bald E; Chwatko G; Nowicki M
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.